Nuclear factor (erythroid-derived 2)-like 2 (NFE2L2) is a novel therapeutic target for diabetic complications

Journal of International Medical Research

Volumn 41, Issue 1, 2013, Pages 13-19

  Xu, Xiaohong ^a,b   Luo, Ping ^a   Wang, Yangwei ^a   Cui, Yingchun ^a   Miao, Lining ^a  

^a THE SECOND HOSPITAL OF JILIN UNIVERSITY   (China)

^b Second Hospital of Xiamen   (China)

Author keywords

Diabetic cardiomyopathy; Diabetic complications; Diabetic nephropathy; Diabetic neuropathy; Diabetic retinopathy; NFE2L2

Indexed keywords

BARDOXOLONE METHYL; CINNAMALDEHYDE; ELECTROPHILE; FUMARIC ACID DIMETHYL ESTER; HEME OXYGENASE 1; OLTIPRAZ; RESVERATROL; SULFORAPHANE; TRANSCRIPTION FACTOR NRF2; ZINC;

CAUSE OF DEATH; DIABETIC CARDIOMYOPATHY; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC PATIENT; DIABETIC RETINOPATHY; DISABILITY; DRUG TARGETING; HEART FAILURE; HUMAN; HYPERGLYCEMIA; IN VITRO STUDY; IN VIVO STUDY; KIDNEY FAILURE; MORTALITY; NEUROPATHY; NONHUMAN; ORGAN INJURY; OXIDATIVE STRESS; PROPHYLAXIS; PROTEIN FUNCTION; REVIEW; SYMPTOM; VISUAL IMPAIRMENT;

EID: 84878386752     PISSN: 03000605     EISSN: 14732300     Source Type: Journal    
DOI: 10.1177/0300060513477004     Document Type: Review

References (65)

1. Gardner DG, Shoback D (eds) Greenspan's Basic and Clinical Endocrinology, 9th edn. New York: McGraw-Hill, 2011.
2. Melmed S, Polonsky KS, Larsen PR, et al. (eds) Williams Textbook of Endocrinology, 12th edn. Philadelphia: Elsevier, 2011.
3. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 2003; 26(suppl 1): S5-S20.
4. Lambert P and Bingley PJ. What is type 1 diabetes? Medicine 2006; 34: 47-51.
5. Vijan S. Type 2 diabetes. Ann Intern Med 2010; 152: ITC3-1-ITC3-15.
6. Nathan DM, Cleary PA, Backlund JY, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005; 353: 2643-2653.
7. The Diabetes Control and Complications Trial Research Group. The effect of intensive diabetes therapy on the development and progression of neuropathy. Ann Intern Med 1995; 122: 561-568.
8. Weiss JS and Sumpio BE. Review of prevalence and outcome of vascular disease in patients with diabetes mellitus. Eur J Vasc Endovasc Surg 2006; 31: 143-150.
9. Moi P, Chan K, Asunis I, et al. Isolation of NF-E2-related factor 2 (Nrf2), a NF-E2-like basic leucine zipper transcriptional activator that binds to the tandem NF-E2/AP1 repeat of the β-globin locus control region. Proc Natl Acad Sci USA 1994; 91: 9926-9930.
10. Kaspar JW, Niture SK and Jaiswal AK. Nrf2:INrf2(Keap1) signaling in oxidative stress. Free Radic Biol Med 2009; 47: 1304-1309.
11. Itoh K, Wakabayashi N, Katoh Y, et al. Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain. Genes Dev 1999; 13: 76-86.
12. Rushmore TH, Morton MR and Pickett CB. The antioxidant responsive element. Activation by oxidative stress and identification of the DNA consensus sequence required for functional activity. J Biol Chem 1991; 266: 11632-11639.
13. Kensler TW, Wakabayashi N and Biswal S. Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway. Annu Rev Pharmacol Toxicol 2007; 47: 89-116.
14. Venugopal R and Jaiswal AK. Nrf1 and Nrf2 positively and c-Fos and Fra1 negatively regulate the human antioxidant response element-mediated expression of NAD(P)H:quinone oxidoreductase1 gene. Proc Natl Acad Sci USA 1996; 93: 14960-14965.
15. Solis WA, Dalton TP, Dieter MZ, et al. Glutamate-cysteine ligase modifier subunit: mouse Gclm gene structure and regulation by agents that cause oxidative stress. Biochem Pharmacol 2002; 63: 1739-1754.
16. Jarmi T and Agarwal A. Heme oxygenase and renal disease. Curr Hypertens Rep 2009; 11: 56-62.
17. Wang J and Doré S. Heme oxygenase-1 exacerbates early brain injury after intracerebral haemorrhage. Brain 2007; 130: 1643-1652.
18. Venugopal R and Jaiswal AK. Nrf2 and Nrf1 in association with Jun proteins regulate antioxidant response element-mediated expression and coordinated induction of genes encoding detoxifying enzymes. Oncogene 1998; 17: 3145-3156.
19. Numazawa S and Yoshida T. Nrf2-dependent gene expressions: a molecular toxicological aspect. J Toxicol Sci 2004; 29: 81-89.
20. Surh YJ, Kundu JK and Na HK. Nrf2 as a master redox switch in turning on the cellular signaling involved in the induction of cytoprotective genes by some chemopreventive phytochemicals. Planta Med 2008; 74: 1526-1539.
21. Yu ZW, Li D, Ling WH, et al. Role of nuclear factor (erythroid-derived 2)-like 2 in metabolic homeostasis and insulin action: a novel opportunity for diabetes treatment? World J Diabetes 2012; 3: 19-28.
22. Berkman J and Rifkin H. Unilateral nodular diabetic glomerulosclerosis (Kimmelstiel-Wilson): report of a case. Metabolism 1973; 22: 715-722.
23. Negi G, Kumar A, Joshi RP, et al. Oxidative stress and diabetic neuropathy: current status of antioxidants. IIOAB Journal 2011; 2: 71-78 (available at: http://www.iioab.org/ Vol2(6)July2011/2(6)71-78.pdf).
24. Debnam ES and Unwin RJ. Hyperglycemia and intestinal and renal glucose transport: implications for diabetic renal injury. Kidney Int 1996; 50: 1101-1109.
25. Jeong SO, Oh GS, Ha HY, et al. Dimethoxycurcumin, a synthetic curcumin analogue, induces heme oxygenase-1 expression through Nrf2 activation in RAW264.7 macrophages. J Clin Biochem Nutr 2009; 44: 79-84.
26. Fridlyand LE and Philipson LH. Oxidative reactive species in cell injury: mechanisms in diabetes mellitus and therapeutic approaches. Ann N Y Acad Sci 2005; 1066: 136-151.
27. Zhang DD. Mechanistic studies of the Nrf2-Keap1 signaling pathway. Drug Metab Rev 2006; 38: 769-789.
28. Yoh K, Hirayama A, Ishizaki K, et al. Hyperglycemia induces oxidative and nitrosative stress and increases renal functional impairment in Nrf2-deficient mice. Genes Cells 2008; 13: 1159-1170.
29. Jiang T, Huang Z, Lin Y, et al. The protective role of Nrf2 in streptozotocin-induced diabetic nephropathy. Diabetes 2010; 59: 850-860.
30. Pergola PE, Krauth M, Huff JW, et al. Effect of bardoxolone methyl on kidney function in patients with T2D and Stage 3 b-4 CKD. Am J Nephrol 2011; 33: 469-476.
31. Zheng H, Whitman SA, Wu W, et al. Therapeutic potential of Nrf2 activators in streptozotocin-induced diabetic nephropathy. Diabetes 2011; 60: 3055-3066.
32. Edwards JL, Vincent AM, Cheng HT, et al. Diabetic neuropathy: mechanisms to management. Pharmacol Ther 2008; 120: 1-34.
33. Figueroa-Romero C, Sadidi M and Feldman EL. Mechanisms of disease: the oxidative stress theory of diabetic neuropathy. Rev Endocr Metab Disord 2008; 9: 301-314.
34. Negi G, Kumar A and Sharma SS. Melatonin modulates neuroinflammation and oxidative stress in experimental diabetic neuropathy: effects on NF-kB and Nrf2 cascades. J Pineal Res 2011; 50: 124-131.
35. Uno K, Prow TW, Bhutto IA, et al. Role of Nrf2 in retinal vascular development and the vaso-obliterative phase of oxygeninduced retinopathy. Exp Eye Res 2010; 90: 493-500.
36. Avogaro A, Vigili de Kreutzenberg S, Negut C, et al. Diabetic cardiomyopathy: a metabolic perspective. Am J Cardiol 2004; 93: 13 A-16 A.
37. Ferri C, Piccoli A, Laurenti O, et al. Atrial natriuretic factor in hypertensive and normotensive diabetic patients. Diabetes Care 1994; 17: 195-200.
38. Fonarow GC and Srikanthan P. Diabetic cardiomyopathy. Endocrinol Metab Clin North Am 2006; 35: 575-599.
39. Balaban RS, Nemoto S and Finkel T. Mitochondria, oxidants, and aging. Cell 2005; 120: 483-495.
40. Walter MF, Jacob RF, Jeffers B, et al. Serum levels of thiobarbituric acid reactive substances predict cardiovascular events in patients with stable coronary artery disease: a longitudinal analysis of the PREVENT study. J Am Coll Cardiol 2004; 44: 1996-2002.
41. Robertson RP. Chronic oxidative stress as a central mechanism for glucose toxicity in pancreatic islet beta cells in diabetes. J Biol Chem 2004; 279: 42351-42354.
42. Rottkanmp CA, Nunomura A, Raina AK, et al. Oxidative stress, antioxidants, and Alzheimer disease. Alzheimer Dis Assoc Disord 2000; 14(suppl 1): S62-S66.
43. Harrison D, Griendling KK, Landmesser U, et al. Role of oxidative stress in atherosclerosis. Am J Cardiol 2003; 91: 7 A-11 A.
44. Donovan EL, McCord JM, Reuland DJ, et al. Phytochemical activation of Nrf2 protects human coronary artery endothelial cells against an oxidative challenge. Oxid Med Cell Longev 2012; 2012: 132931.
45. Ungvari Z, Bagi Z, Feher A, et al. Resveratrol confers endothelial protection via activation of the antioxidant transcription factor Nrf2. Am J Physiol Heart Circ Physiol 2010; 299: H18-H24.
46. Ungvari Z, Labinskyy N, Mukhopadhyay P, et al. Resveratrol attenuates mitochondrial oxidative stress in coronary arterial endothelial cells. Am J Physiol Heart Circ Physiol 2009; 297: H1876-H1881.
47. Ungvari Z, Orosz Z, Rivera A, et al. Resveratrol increases vascular oxidative stress resistance. Am J Physiol Heart Circ Physiol 2007; 292: H2417-H2424.
48. Ungvari Z, Parrado-Fernandez C, Csiszar A, et al. Mechanisms underlying caloric restriction and lifespan regulation: implications for vascular aging. Circ Res 2008; 102: 519-528.
49. Gürler B, Vural H, Yilmaz N, et al. The role of oxidative stress in diabetic retinopathy. Eye (Lond) 2000; 14: 730-735.
50. Kowluru RA and Chan PS. Oxidative stress and diabetic retinopathy. Exp Diabetes Res 2007; 2007: 43603.
51. Sperber GO and Bill A. Blood flow and glucose consumption in the optic nerve, retina and brain: effects of high intraocular pressure. Exp Eye Res 1985; 41: 639-653.
52. Zhao Z, Chen Y, Wang J, et al. Age-related retinopathy in NRF2-deficient mice. PLoS One 2011; 6: e19456.
53. Wei Y, Gong J, Yoshida T, et al. Nrf2 has a protective role against neuronal and capillary degeneration in retinal ischemia-reperfusion injury. Free Radic Biol Med 2011; 51: 216-224.
54. Nguyen T, Nioi P and Pickett CB. The Nrf2-antioxidant response element signaling pathway and its activation by oxidative stress. J Biol Chem 2009; 284: 13291-13295.
55. Maher P and Hanneken A. Flavonoids protect retinal ganglion cells from oxidative stress-induced death. Invest Ophthalmol Vis Sci 2005; 46: 4796-4803.
56. Fan JW and Xu GZ. Heme oxygenase-1 mediates Nrf2-dependent protection of neurons and vascular endothelial cells in diabetic retinopathy. Invest Ophthalmol Vis Sci 2011; 52: E-Abstract 4446.
57. Chen J, Wang L, Chen Y, et al. Phosphatidylinositol 3 kinase pathway and 4-hydryoxy-2-nonenal-induced oxidative injury in the RPE. Invest Ophthalmol Vis Sci 2009; 50: 936-942.
58. He M, Cai J, Go YM, et al. Identification of thioredoxin-2 as a regulator of the mitochondrial permeability transition. Toxicol Sci 2008; 105: 44-50.
59. Chen Y, Go YM, Pohl J, et al. Increased mitochondrial thioredoxin 2 potentiates N-ethylmaleimide-induced cytotoxicity. Chem Res Toxicol 2008; 21: 1205-1210.
60. Wang L, Chen Y, Sternberg P, et al. Essential roles of the PI3 kinase/Akt pathway in regulating Nrf2-dependent antioxidant functions in the RPE. Invest Ophthalmol Vis Sci 2008; 49: 1671-1678.
61. Landers RA, and Bingaman DP: Agents for Treatment of Diabetic Retinopathy and Drusen Formation in Macular Degeneration, 2010 (available at: http://www.faqs.org/ patents/app/20100204244#b#ixzz1r tyIay1q).
62. Janghorbani M, Van Dam RM, Willett WC, et al. Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture. Am J Epidemiol 2007; 166: 495-505.
63. Lu H, Kraut D, Gerstenfeld LC, et al. Diabetes interferes with the bone formation by affecting the expression of transcription factors that regulate osteoblast differentiation. Endocrinology 2003; 144: 346-352.
64. Wruck CJ, Fragoulis A, Guzynski A, et al. Role of oxidative stress in rheumatoid arthritis: insights from the Nrf2-knockout mice. Ann Rheum Dis 2011; 70: 844-850.
65. Maicas N, Ferrándiz ML, Brines R, et al. Deficiency of Nrf2 accelerates the effector phase of arthritis and aggravates joint disease. Antioxid Redox Signal 2011; 15: 889-901.